Antipsychotics carry a higher-risk profile than other psychotropic medications and may be prescribed for youth with conditions in which other first-line treatments are more appropriate. This study aimed to evaluate the population-level effect of the Safer Use of Antipsychotics in Youth (SUAY) trial, which aimed to reduce person-days of antipsychotic use among participants.
Methods:
We conducted an interrupted time series analysis using segmented regression to measure changes in prescribing trends of antipsychotic initiation rates pre-SUAY and post-SUAY trial at four U.S. health systems between 2013 and 2020.
Results:
In our overall model, adjusted for age and insurance type, antipsychotic initiation rates decreased by 0.73 (95% confidence interval [CI]: 0.30, 1.16, p = 0.002) prescriptions per 10,000 person-months before the SUAY trial. In the first quarter following the start of the trial, there was an immediate decrease in the rate of antipsychotic initiations of 6.57 (95% CI: 0.99, 12.15) prescriptions per 10,000 person-months. When comparing the posttrial period to the pretrial period, there was an increase of 1.09 (95% CI: 0.32, 1.85) prescriptions per 10,000 person-months, but the increasing rate in the posttrial period alone was not statistically significant (0.36 prescriptions per 10,000 person-months, 95% CI: −0.27, 0.99).
Conclusion:
The declining trend of antipsychotic initiation seen between 2013 and 2018 (pre-SUAY trial) may have naturally reached a level at which prescribing was clinically warranted and appropriate, resulting in a floor effect. The COVID-19 pandemic, which began in the final three quarters of the posttrial period, may also be related to increased antipsychotic medication initiation.
Get full access to this article
View all access options for this article.
References
1.
AkincigilA, MackieTI, CookS, et al.Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children. Health Serv Res, 2020; 55(4):596–603; doi: 10.1111/1475-6773.13297
2.
BarclayRP, PenfoldRB, SullivanD, et al.Decrease in statewide antipsychotic prescribing after implementation of child and adolescent psychiatry consultation services. Health Serv Res, 2017; 52(2):561–578; doi: 10.1111/1475-6773.12539
3.
BeckerSP, BreauxR, CusickCN, et al.Remote learning during COVID-19: Examining school practices, service continuation, and difficulties for adolescents with and without attention-deficit/hyperactivity disorder. J Adolesc Health, 2020; 67(6):769–777; doi: 10.1016/j.jadohealth.2020.09.002
4.
BernalJL, CumminsS, GasparriniA. Interrupted time series regression for the evaluation of public health interventions: A tutorial. Int J Epidemiol, 2017; 46(1):348–355; doi: 10.1093/ije/dyw098
5.
BoboE, LinL, AcquavivaE, et al.How do children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) experience lockdown during the COVID-19 outbreak? Encephale, 2020; 46(3S):S85–S92; doi: 10.1016/j.encep.2020.05.011
6.
BretlerT, WeisbergH, KorenO, et al.The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med, 2019; 17(1):112; doi: 10.1186/s12916-019-1346-1
7.
BrunetteMF, CotesRO, de NesneraA, et al.Use of academic detailing with audit and feedback to improve antipsychotic pharmacotherapy. Psychiatr Serv, 2018; 69(9):1021–1028; doi: 10.1176/appi.ps.201700536
8.
BushnellGA, CrystalS, OlfsonM. Trends in antipsychotic medication use in young privately insured children. J Am Acad Child Adolesc Psychiatry, 2021; 60(7):877–886; doi: 10.1016/j.jaac.2020.09.023
9.
ChavezLJ, KelleherKJ, BeckA, et al.Trends over time in antipsychotic initiation at a large children’s health care system. J Child Adolesc Psychopharmacol, 2021; 31(5):381–386; doi: 10.1089/cap.2020.0190
10.
Cheng-ShannonJ, McGoughJJ, PatakiC, et al.Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol, 2004; 14(3):372–394; doi: 10.1089/cap.2004.14.372
11.
ChristianR, SaavedraL, GaynesBN, et al.Future research needs for first- and second-generation antipsychotics for children and young adults. Agency for Healthcare Research and Quality. Rockville, MD: 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK84660/ [April 8, 24].
12.
ComerJS, OlfsonM, MojtabaiR. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry, 2010; 49(10):1001–1010; doi: 10.1016/j.jaac.2010.07.007
13.
CorrellCU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry, 2008; 69(Suppl 4):26–36.
14.
CorrellCU, ManuP, OlshanskiyV, et al.Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Jama, 2009; 302(16):1765–1773; doi: 10.1001/jama.2009.1549
15.
CorrellCU, CorteseS, CroattoG, et al.Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: An umbrella review. World Psychiatry, 2021; 20(2):244–275; doi: 10.1002/wps.20881
16.
CostalesB, SlamaNE, PenfoldRB, et al.On- and off-label atypical antipsychotic prescription trends across a nine-year period among adolescents pre- to post-COVID-19. Acad Pediatr, 2024; doi: 10.1016/j.acap.2024.03.003S1876-2859(24)00072-X
17.
CrystalS, MackieT, FentonMC, et al.Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Aff (Millwood), 2016; 35(6):974–982; doi: 10.1377/hlthaff.2016.0064
18.
CrystalS, OlfsonM, HuangC, et al.Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood), 2009; 28(5):w770–81; doi: 10.1377/hlthaff.28.5.w770
19.
CurfmanA, McSwainSD, ChuoJ, et al.Pediatric telehealth in the COVID-19 pandemic era and beyond. Pediatrics, 2021; 148(3):e2020047795; doi: 10.1542/peds.2020-047795
20.
EdelsohnGA, KarpovI, ParthasarathyM, et al.Trends in antipsychotic prescribing in Medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry, 2017; 56(1):59–66; doi: 10.1016/j.jaac.2016.10.005
21.
FinnertyMT, KealeyE, Leckman-WestinE, et al.Long-term impact of web-based tools, leadership feedback, and policies on inpatient antipsychotic polypharmacy. Psychiatr Serv, 2011; 62(10):1124–1126; doi: 10.1176/ps.62.10.pss6210_1124
22.
GallingB, RoldánA, NielsenRE, et al.Type 2 diabetes mellitus in youth exposed to antipsychotics: A systematic review and meta-analysis. JAMA Psychiatry, 2016; 73(3):247–259; doi: 10.1001/jamapsychiatry.2015.2923
23.
HawrilenkoM, KroshusE, TandonP, et al.The association between school closures and child mental health during COVID-19. JAMA Netw Open, 2021; 4(9):e2124092; doi: 10.1001/jamanetworkopen.2021.24092
24.
HertzMF, KilmerG, VerlendenJ, et al.Adolescent mental health, connectedness, and mode of school instruction during COVID-19. J Adolesc Health, 2022; 70(1):57–63; doi: 10.1016/j.jadohealth.2021.10.021
25.
HiltRJ, RomaireMA, McDonellMG, et al.The partnership access line: Evaluating a child psychiatry consult program in Washington State. JAMA Pediatr, 2013; 167(2):162–168; doi: 10.1001/2013.jamapediatrics.47
26.
KalverdijkLJ, BachmannCJ, AagaardL, et al.A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child Adolesc Psychiatry Ment Health, 2017; 11:55; doi: 10.1186/s13034-017-0192-1
27.
LindenA. A matching framework to improve causal inference in interrupted time-series analysis. J Eval Clin Pract, 2018; 24(2):408–415; doi: 10.1111/jep.12874
28.
MackieTI, HydeJ, PalinkasLA, et al.Fostering psychotropic medication oversight for children in foster care: A national examination of states' monitoring mechanisms. Adm Policy Ment Health, 2017; 44(2):243–257; doi: 10.1007/s10488-016-0721-x
29.
NicolGE, YinglingMD, FlavinKS, et al.Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: A randomized clinical trial. JAMA Psychiatry, 2018; 75(8):788–796; doi: 10.1001/jamapsychiatry.2018.1088
30.
OlfsonM, BlancoC, LiuL, et al.National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry, 2006; 63(6):679–685; doi: 10.1001/archpsyc.63.6.679
31.
OlfsonM, MarcusSC, WeissmanMM, et al.National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry, 2002; 41(5):514–521; doi: 10.1097/00004583-200205000-00008
32.
OlfsonM, BlancoC, LiuSM, et al.National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry, 2012; 69(12):1247–1256; doi: 10.1001/archgenpsychiatry.2012.647
33.
OlfsonM, KingM, SchoenbaumM. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 2015; 72(9):867–874; doi: 10.1001/jamapsychiatry.2015.0500
34.
PalinkasLA, De LeonJ, SalinasE, et al.Impact of the COVID-19 pandemic on child and adolescent mental health policy and practice implementation. Int J Environ Res Public Health, 2021; 18(18):9622; doi: 10.3390/ijerph18189622
35.
PenfoldRB, StewartC, HunkelerEM, et al.Use of antipsychotic medications in pediatric populations: What do the data say? Curr Psychiatry Rep, 2013; 15(12):426; doi: 10.1007/s11920-013-0426-8
36.
PenfoldRB, ThompsonEE, HiltRJ, et al.Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol. Contemp Clin Trials, 2020; 99:106184; doi: 10.1016/j.cct.2020.106184
37.
PenfoldRB, ZhangF. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr, 2013; 13(6 Suppl):S38–44; doi: 10.1016/j.acap.2013.08.002
38.
PiehC, PlenerPL, ProbstT, et al.Assessment of mental health of high school students during social distancing and remote schooling during the COVID-19 pandemic in Austria. JAMA Netw Open, 2021; 4(6):e2114866; doi: 10.1001/jamanetworkopen.2021.14866
39.
RoyAK, BreauxR, SciberrasE, et al.A preliminary examination of key strategies, challenges, and benefits of remote learning expressed by parents during the COVID-19 pandemic. Sch Psychol, 2022; 37(2):147–159; doi: 10.1037/spq0000465
40.
SchmidI, BurcuM, ZitoJM. Medicaid prior authorization policies for pediatric use of antipsychotic medications. Jama, 2015; 313(9):966–968; doi: 10.1001/jama.2015.0763
ShadishWR, CookTD, CampbellDT. Experimental and quasi-experimental designs for generalized causal inference. Houghton, Mifflin and Company: Boston, MA; 2002.
43.
SoumeraiSB, AvornJ. Principles of educational outreach ('academic detailing') to improve clinical decision making. Jama, 1990; 263(4):549–556.
44.
TaniH, UchidaH, SuzukiT, et al.Interventions to reduce antipsychotic polypharmacy: A systematic review. Schizophr Res, 2013; 143(1):215–220; doi: 10.1016/j.schres.2012.10.015
45.
TripepiG, JagerKJ, DekkerFW, et al.Stratification for confounding–part 2: Direct and indirect standardization. Nephron Clin Pract, 2010; 116(4):c322–5; doi: 10.1159/000319591
46.
WagnerAK, SoumeraiSB, ZhangF, et al.Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther, 2002; 27(4):299–309; doi: 10.1046/j.1365-2710.2002.00430.x
47.
ZitoJM, SaferDJ, dosReisS, et al.Trends in the prescribing of psychotropic medications to preschoolers. Jama, 2000; 283(8):1025–1030; doi: 10.1001/jama.283.8.1025
48.
ZitoJM, BurcuM, McKeanS, et al.Pediatric use of antipsychotic medications before and after Medicaid peer review implementation. JAMA Psychiatry, 2018; 75(1):100–103; doi: 10.1001/jamapsychiatry.2017.3493
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
